EDITORIAL article
Front. Cardiovasc. Med.
Sec. Cardiovascular Pharmacology and Drug Discovery
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1597062
This article is part of the Research TopicTherapeutic Strategies to Lower Residual Dyslipidemic CV Risk Beyond LDL-C and StatinsView all 8 articles
Editorial: Therapeutic Strategies to Lower Residual Dyslipidemic CV Risk Beyond LDL-C and Statins
Provisionally accepted
- 1University of Pisa, Pisa, Italy
- 2UCLA Health System, Los Angeles, California, United States
- 3University of California, Los Angeles, Los Angeles, California, United States
- 4Lundquist Institute for Biomedical Innovation, Torrance, California, United States
- 5Boston University, Boston, Massachusetts, United States
- 6Harvard Medical School, Boston, Massachusetts, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide [1]. Cardiovascular (CV) risk reduction is important in patients at high risk for a first event (primary prevention) and those with established ASCVD (secondary prevention). For decades, statin therapy has been the main therapeutic agent to reduce the risk of CV events. However, even in patients with low-density lipoprotein cholesterol (LDL-C) levels well below guideline-recommended targets, a substantial risk for CV events remains. Therefore, methods are needed to address persistent CV risk in patients taking statins, particularly with additional agents that target pathways beyond LDL-C. Components of the residual risk include inflammation, thrombotic and metabolic factors, and elevated triglyceride (TG) levels. This Special Issue of Frontiers aims at providing a forum for current advances in reducing persistent CV risk in patients taking statins and with persistently elevated TG levels, with a special focus on use of icosapent ethyl (IPE) or eicosapentaenoic acid (EPA), recently come to the worldwide attention after the strikingly favourable findings from the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) [2; 3]. Omega-
Keywords: statin, cardiovascular disease, Icosapent ethyl, Omega-3 fatty Acids, Secondary Prevention, Primary Prevention
Received: 20 Mar 2025; Accepted: 05 May 2025.
Copyright: © 2025 De Caterina, Budoff and Boden. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Raffaele De Caterina, University of Pisa, Pisa, Italy
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.